Comprehensive Therapy

, Volume 32, Issue 2, pp 102–105 | Cite as

Planning for the HPV vaccine and its impact on cervical cancer prevention

  • Justin Bailey
  • Tyler Childs Cymet
Original Articles


Genital human papilloma virus (HPV), the most common sexually transmitted disease in the United States, is associated with cervical cancer in women, and penile cancers in men. The infection is asymptomatic until a malignancy develops. Of the more than 90 subtypes, only a small number are associated with malignancies. Vaccines made with recombinant HPV proteins have been shown effective in preventing infection with the more virulent strains of the virus.


Human Papilloma Virus Genital Wart Human Papilloma Virus Infection Penile Cancer Comp THER 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527.PubMedCrossRefGoogle Scholar
  2. 2.
    Cupp MR, Malek RS, Goellner JR, Smith TF, Espy MJ, The detection of human papillomavirus deoxyribonucleic acid in intraepithelial, in situ, verrucous and invasive carcinoma of the penis. J Urol 1995;154:1024–1029.PubMedCrossRefGoogle Scholar
  3. 3.
    Frisch M. On the etiology of anal squamous carcinoma. Dan Med Bull 2002;49:194–209.PubMedGoogle Scholar
  4. 4.
    Stubenrauch F, Laimins LA. Human papillomavirus life cycle: active and latent phases. Semin. Cancer Biol 1999;9:379–386.PubMedCrossRefGoogle Scholar
  5. 5.
    Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423–428.PubMedCrossRefGoogle Scholar
  6. 6.
    Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157:218–226.PubMedCrossRefGoogle Scholar
  7. 7.
    Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004;4:46–54.PubMedCrossRefGoogle Scholar
  8. 8.
    Burk RD. Human papillomavirus and the risk of cervical cancer. Hosp Pract (Off Ed) 1999;34:103–111.Google Scholar
  9. 9.
    Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Rhea WG Jr, Bourgeois BM, Sewell DR. Condyloma acuminata: a fatal disease? Am Surg 1998;64:1082–1087.PubMedGoogle Scholar
  11. 11.
    Bosch FX, Castellsague X, Munoz N, et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer Inst 1996;88:1060–1067.PubMedCrossRefGoogle Scholar
  12. 12.
    Lajous M, Mueller N, Cruz-Valdez A, et al. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 2005;14:1710–1716.PubMedCrossRefGoogle Scholar
  13. 13.
    Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21–31.PubMedCrossRefGoogle Scholar
  14. 14.
    Moscicki AB, Hills N, Shiboski S, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001;285:2995–3002.PubMedCrossRefGoogle Scholar
  15. 15.
    ACOG practice bulletin. Cervical cytology screening. Int J Gynaecol Obstet 2003;83:237–247.Google Scholar
  16. 16.
    Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308–317.PubMedCrossRefGoogle Scholar
  17. 17.
    White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA. In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol 1998;72:959–964.PubMedGoogle Scholar
  18. 18.
    Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271–278.PubMedCrossRefGoogle Scholar
  19. 19.
    Mao C, Koutsky LA, Ault KA, et al. Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial. Obstet Gynecol 2006;107:18–27.PubMedGoogle Scholar
  20. 20.
    Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645–1651.PubMedCrossRefGoogle Scholar
  21. 21.
    Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nat Rev Microbiol 2004;2:343–347.PubMedCrossRefGoogle Scholar
  22. 22.
    Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489–490.PubMedCrossRefGoogle Scholar
  23. 23.
    Jastreboff AM, Cymet TC. Role of human papilloma virus in the development of cervical intraepithelial neoplasi and malignancy Postgrad Med J 2002;78:225–228PubMedCrossRefGoogle Scholar

Copyright information

© ASCMS 2006

Authors and Affiliations

  1. 1.Johns Hopkins School of MedicineBaltimore

Personalised recommendations